These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
170 related articles for article (PubMed ID: 12857964)
1. Regulation, counter-regulation, and immunotherapy of autoimmune responses to immunologically privileged retinal antigens. Caspi RR Immunol Res; 2003; 27(2-3):149-60. PubMed ID: 12857964 [TBL] [Abstract][Full Text] [Related]
2. Modulating of ocular inflammation with macrophage migration inhibitory factor is associated with notch signalling in experimental autoimmune uveitis. Yang H; Zheng S; Mao Y; Chen Z; Zheng C; Li H; Sumners C; Li Q; Yang P; Lei B Clin Exp Immunol; 2016 Feb; 183(2):280-93. PubMed ID: 26400205 [TBL] [Abstract][Full Text] [Related]
3. [Contribution of immunologic mechanisms in endogenous uveitis]. Kubicka A Klin Oczna; 1995; 97(3-4):90-2. PubMed ID: 7474804 [TBL] [Abstract][Full Text] [Related]
4. A new model of autoimmune disease. Experimental autoimmune uveoretinitis induced in mice with two different retinal antigens. Caspi RR; Roberge FG; Chan CC; Wiggert B; Chader GJ; Rozenszajn LA; Lando Z; Nussenblatt RB J Immunol; 1988 Mar; 140(5):1490-5. PubMed ID: 3346541 [TBL] [Abstract][Full Text] [Related]
5. [The suppression of the experimental autoimmune uveoretinitis with retinal S antigens by intranasal tolerance induction]. Zheng YZ; Yuan LL; Lin JY; Li HQ Zhonghua Yan Ke Za Zhi; 2006 Dec; 42(12):1118-22. PubMed ID: 17415971 [TBL] [Abstract][Full Text] [Related]
6. Suppression of experimental autoimmune uveitis in Lewis rats by oral administration of recombinant Escherichia coli expressing retinal S-antigen. Singh VK; Anand R; Sharma K; Agarwal SS Cell Immunol; 1996 Sep; 172(2):158-62. PubMed ID: 8964076 [TBL] [Abstract][Full Text] [Related]
7. Spontaneously relapsing-remitting experimental autoimmune uveitis in rats allows successful therapeutic oral tolerance induction in ongoing disease. Huber A; Diedrichs-Möhring M; Wildner G Mol Immunol; 2015 Feb; 63(2):215-26. PubMed ID: 25085538 [TBL] [Abstract][Full Text] [Related]
8. Bench to bedside: new approaches to the immunotherapy of uveitic disease. Nussenblatt RB Int Rev Immunol; 2002; 21(2-3):273-89. PubMed ID: 12424847 [TBL] [Abstract][Full Text] [Related]
10. Proctor Lecture. Experimental autoimmune uveitis: mechanisms of disease and clinical therapeutic indications. Nussenblatt RB Invest Ophthalmol Vis Sci; 1991 Dec; 32(13):3131-41. PubMed ID: 1748544 [No Abstract] [Full Text] [Related]
11. Experimental autoimmune uveoretinitis (EAU)-related tissue damage and angiogenesis is reduced in CCL2⁻/⁻CX₃CR1gfp/gfp mice. Zhao J; Chen M; Xu H Invest Ophthalmol Vis Sci; 2014 Oct; 55(11):7572-82. PubMed ID: 25342612 [TBL] [Abstract][Full Text] [Related]
12. The Role of αA-Crystallin in Experimental Autoimmune Uveitis. Wang L; Zhang L; Wang ZF; Huang ZX; Hu X; Gong L; Tang X; Liu F; Luo Z; Ji W; Hu WF; Woodward Z; Zhu J; Liu YZ; Nguyen QD; Li DW Curr Mol Med; 2015; 15(6):558-64. PubMed ID: 26238368 [TBL] [Abstract][Full Text] [Related]
13. Evidence for selective accumulation of V beta 8+ T lymphocytes in experimental autoimmune uveoretinitis induced with two different retinal antigens. Egwuagu CE; Mahdi RM; Nussenblatt RB; Gery I; Caspi RR J Immunol; 1993 Aug; 151(3):1627-36. PubMed ID: 8393049 [TBL] [Abstract][Full Text] [Related]